Replimune Group (REPL) has issued an update.
Replimune Group, Inc. has entered into a private placement agreement with key investors to sell over 5.6 million shares and an equivalent number of pre-funded warrants, aiming to raise approximately $100 million to fund the commercialization of their skin cancer treatment, RP1, and for general corporate purposes. The deal includes a commitment to register the securities for resale, ensuring investors can trade them on the open market, subject to regulatory conditions. This strategic move highlights the company’s proactive steps in scaling up their operations and solidifying their financial foundation for future growth.
See more data about REPL stock on TipRanks’ Stock Analysis page.
